Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:ETON NASDAQ:MNPR NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.89+2.1%$3.14$2.71▼$6.98$142.88M1.16164,735 shs78,731 shsETONEton Pharmaceuticals$19.15+2.0%$18.23$7.58▼$23.00$513.60M1.16355,132 shs235,121 shsMNPRMonopar Therapeutics$90.42-5.1%$56.42$4.50▼$105.00$557.89M1.4245,423 shs60,911 shsPRTAProthena$10.66+5.3%$8.74$4.32▼$18.88$573.83M-0.111.02 million shs801,906 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-1.05%-0.35%-16.02%-30.98%-45.58%ETONEton Pharmaceuticals+3.82%-11.25%+6.35%+35.13%+129.18%MNPRMonopar Therapeutics-6.62%-3.28%+93.60%+132.02%+1,667.90%PRTAProthena-2.22%-0.49%+23.26%+60.13%-41.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.89+2.1%$3.14$2.71▼$6.98$142.88M1.16164,735 shs78,731 shsETONEton Pharmaceuticals$19.15+2.0%$18.23$7.58▼$23.00$513.60M1.16355,132 shs235,121 shsMNPRMonopar Therapeutics$90.42-5.1%$56.42$4.50▼$105.00$557.89M1.4245,423 shs60,911 shsPRTAProthena$10.66+5.3%$8.74$4.32▼$18.88$573.83M-0.111.02 million shs801,906 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-1.05%-0.35%-16.02%-30.98%-45.58%ETONEton Pharmaceuticals+3.82%-11.25%+6.35%+35.13%+129.18%MNPRMonopar Therapeutics-6.62%-3.28%+93.60%+132.02%+1,667.90%PRTAProthena-2.22%-0.49%+23.26%+60.13%-41.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.00Hold$6.00107.61% UpsideETONEton Pharmaceuticals 2.40Hold$29.6754.92% UpsideMNPRMonopar Therapeutics 3.00Buy$105.6716.86% UpsidePRTAProthena 2.20Hold$20.5092.31% UpsideCurrent Analyst Ratings BreakdownLatest BTMD, MNPR, PRTA, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$125.0010/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$125.0010/10/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025BTMDbioteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)10/8/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRTAProthenaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $20.0010/7/2025ETONEton PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/6/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$80.00 ➝ $142.0010/2/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$77.00 ➝ $115.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$199.07M0.72$0.77 per share3.73($2.78) per share-1.04ETONEton Pharmaceuticals$39.01M13.17N/AN/A$0.94 per share20.37MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/APRTAProthena$10.34M55.49N/AN/A$9.05 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.903.215.35N/A15.73%-21.00%18.26%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A38.30N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)PRTAProthena-$122.31M-$5.64N/AN/AN/A-2,929.30%-62.17%-54.43%11/11/2025 (Estimated)Latest BTMD, MNPR, PRTA, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BTMDbiote$0.05N/AN/AN/A$47.76 millionN/A11/11/2025Q3 2025ETONEton Pharmaceuticals$0.13N/AN/AN/A$20.47 millionN/A11/11/2025Q3 2025PRTAProthena-$0.60N/AN/AN/A$6.64 millionN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 million8/6/2025Q2 2025BTMDbiote$0.06$0.10+$0.04$0.10$49.52 million$48.86 million8/4/2025Q2 2025PRTAProthena-$1.11-$1.86-$0.75-$2.34$5.36 million$4.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A0.980.74ETONEton Pharmaceuticals1.141.771.16MNPRMonopar TherapeuticsN/A33.9333.93PRTAProthenaN/A5.685.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%ETONEton Pharmaceuticals27.86%MNPRMonopar Therapeutics1.83%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipBTMDbiote24.00%ETONEton Pharmaceuticals14.89%MNPRMonopar Therapeutics20.50%PRTAProthena10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19449.44 million37.57 millionNot OptionableETONEton Pharmaceuticals2026.82 million22.83 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionablePRTAProthena13053.83 million48.45 millionOptionableBTMD, MNPR, PRTA, and ETON HeadlinesRecent News About These CompaniesFY2029 EPS Estimates for Prothena Raised by HC WainwrightOctober 11, 2025 | americanbankingnews.comFY2029 EPS Estimates for Prothena Boosted by HC WainwrightOctober 10, 2025 | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for Prothena (NASDAQ:PRTA)October 10, 2025 | marketbeat.comDeep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)October 7, 2025 | benzinga.comPublic Employees Retirement System of Ohio Invests $256,000 in Prothena Corporation plc $PRTAOctober 7, 2025 | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comProthena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of ...October 1, 2025 | pharmiweb.comPProthena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's DiseaseOctober 1, 2025 | businesswire.comProthena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average - Should You Sell?September 23, 2025 | marketbeat.comGoldman Sachs Group Inc. Decreases Position in Prothena Corporation plc $PRTASeptember 16, 2025 | marketbeat.comWhat is Zacks Research's Estimate for Prothena Q1 Earnings?September 16, 2025 | marketbeat.comProthena Down 40% Year to Date: What Lies Ahead for the Stock?September 11, 2025 | zacks.comProthena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?September 3, 2025 | zacks.comProthena provides mixed update on PRX012August 30, 2025 | thepharmaletter.comTProthena Corporation plc: Prothena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | finanznachrichten.deProthena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | businesswire.comProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical ProgramAugust 27, 2025 | businesswire.comCitizens JMP Remains a Buy on Prothena (PRTA)August 9, 2025 | theglobeandmail.comNovo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns HopefulAugust 7, 2025 | msn.comProthena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with CardiomyopathyAugust 6, 2025 | businesswire.com9 Analysts Assess Prothena Corp: What You Need To KnowAugust 5, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTMD, MNPR, PRTA, and ETON Company Descriptionsbiote NASDAQ:BTMD$2.89 +0.06 (+2.12%) Closing price 04:00 PM EasternExtended Trading$2.89 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Eton Pharmaceuticals NASDAQ:ETON$19.15 +0.38 (+2.02%) Closing price 04:00 PM EasternExtended Trading$18.76 -0.39 (-2.04%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Monopar Therapeutics NASDAQ:MNPR$90.42 -4.87 (-5.11%) Closing price 04:00 PM EasternExtended Trading$90.64 +0.22 (+0.24%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Prothena NASDAQ:PRTA$10.66 +0.54 (+5.34%) Closing price 04:00 PM EasternExtended Trading$10.76 +0.10 (+0.89%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
